New pharmaceutical agents, sustained-release delivery systems, biologic therapies, and presbyopia treatments are moving the ophthalmic therapeutic market toward mechanism-based treatment selection, reduced preservative exposure, and delivery platforms that are designed to improve adherence and reduce treatment burden, said Mitch Ibach, OD, FAAO, and Jake Lang, OD, FAAO, in their “Drops, Drugs, and Delivery: What’s New in Ophthalmic Therapeutics” presentation at Optometry’s Meeting 2026 in...